Abstract
When evaluating the design of pre-clinical studies in the field of traumatic brain injury, we found substantial differences compared to phase III clinical trials, which in part may explain the difficulties in translating promising experimental drugs into approved treatments. By using network analysis, we also found cases where a large proportion of the studies evaluating a pre-clinical treatment was performed by inter-related researchers, which is potentially problematic. Subjecting all pre-clinical trials to the rigor of a phase III clinical trial is, however, likely not practically achievable. Instead, we repeat the call for a distinction to be made between exploratory and confirmatory pre-clinical studies.
References
Jun 5, 1999·Science·J C CrabbeB C Dudek
Dec 3, 1999·Stroke; a Journal of Cerebral Circulation·UNKNOWN Stroke Therapy Academic Industry Roundtable (STAIR)
Oct 22, 2003·Journal of Neurosurgery·Chantal W P M HukkelhovenAndrew I R Maas
Apr 13, 2005·Lancet·Kenneth F Schulz, David A Grimes
May 27, 2005·Neurosurgical Focus·M Ross BullockGraham M Teasdale
Mar 23, 2007·Journal of Neurotrauma·Andrew I R MaasEwout W Steyerberg
Jul 9, 2010·PLoS Biology·Carol KilkennyDouglas G Altman
Apr 11, 2013·Nature Reviews. Neuroscience·Katherine S ButtonMarcus R Munafò
May 23, 2014·PLoS Biology·Jonathan KimmelmanUlrich Dirnagl
Jul 22, 2014·European Journal of Clinical Investigation·Sanne J Jansen of LorkeersSteven A J Chamuleau
Mar 15, 2015·PLoS Biology·Megan L HeadMichael D Jennions
Aug 6, 2015·PloS One·Robert M Kaplan, Veronica L Irvin
Oct 16, 2015·PLoS Biology·Malcolm R MacleodEmily S Sena
Dec 17, 2015·Journal of Neurotrauma·Patrick M KochanekFrank C Tortella
Dec 30, 2015·Journal of Neurotrauma·Peter BraggeRussell L Gruen
Feb 24, 2017·Nature·Jeffrey S Mogil, Malcolm R Macleod